Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOFOL vs FLUOTHANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in the ICU,Procedural sedation (e.g., during diagnostic or therapeutic procedures),Treatment of refractory status epilepticus (off-label),Management of severe agitation or delirium (off-label)
Induction and maintenance of general anesthesia,Off-label: Use for status asthmaticus (rarely)
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Primarily hepatic via conjugation to glucuronide and sulfate; also metabolized by CYP2B6 and CYP2C9. Metabolites are renally excreted.
Hepatic metabolism via cytochrome P450 enzymes (CYP2E1 major, CYP2A6 minor) to trifluoroacetic acid, chloride, and bromide ions; reductive metabolism under hypoxic conditions produces potentially hepatotoxic intermediates.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
95-99% bound primarily to albumin (≈48%) and alpha-1-acid glycoprotein (≈50%), with minor binding to lipoproteins.
~40-50% bound to albumin.
Initial Vd: 0.2-0.4 L/kg (central compartment); steady-state Vd: 2-10 L/kg (extensive tissue distribution).
2-5 L/kg; indicates extensive tissue distribution, particularly in adipose and brain.
IV: 100%; enteral: negligible due to first-pass metabolism; oral bioavailability <1%.
Inhalation: 100% (administered as gas); no other relevant routes.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, use with caution due to propylene glycol accumulation, monitor for metabolic acidosis.
No dose adjustment required for renal impairment; halothane is minimally excreted renally.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce by 75% due to prolonged clearance and risk of hypotension.
Contraindicated in patients with Child-Pugh class B or C cirrhosis due to risk of hepatotoxicity; use with caution in mild impairment with reduced doses.
Induction: 2.5-3.5 mg/kg IV over 30 sec. Maintenance: 125-300 mcg/kg/min for age <3 years; 100-200 mcg/kg/min for age 3-12 years. For sedation: 25-100 mcg/kg/min.
Induction: 0.5-2% halothane in oxygen; maintenance: 0.3-1%. Dose based on response.
Reduce induction dose to 1-1.5 mg/kg IV; decrease infusion rate by 20-50% due to reduced clearance and increased sensitivity.
Reduce induction concentration to 0.5-1% and maintenance to 0.5% due to increased sensitivity and slower clearance.
No FDA black box warnings.
Halothane is associated with a risk of life-threatening hepatic injury, including fatal hepatic necrosis, primarily following repeated exposure or in patients with known hypersensitivity. It should be avoided in patients with a history of unexplained jaundice or fever after halothane administration.
Hypotension and bradycardia: may require fluid resuscitation or vasopressors,Respiratory depression and apnea: must have airway management equipment available,Propofol infusion syndrome (PRIS): rare but fatal with high doses >4 mg/kg/hr for >48 hours; characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure,Risk of pancreatitis: monitor lipase if symptoms develop,Abrupt discontinuation may cause withdrawal symptoms after prolonged use,Not recommended for use in patients with propofol allergy or egg/soybean oil hypersensitivity (formulation contains egg lecithin and soybean oil)
Risk of hepatic necrosis (especially with repeated use); malignant hyperthermia; respiratory depression; hypotension; cardiac arrhythmias (including sensitization to catecholamines); increased intracranial pressure; requires trained personnel and monitoring; use caution in patients with hepatic disease.
Hypersensitivity to propofol or any component of the formulation (including egg lecithin, soybean oil, or disodium edetate),Patients with severe lipid metabolism disorders (e.g., pancreatitis with hypertriglyceridemia),Not for use in general anesthesia in obstetrics (crosses placenta; may cause neonatal depression),Relative: hypovolemia, hemodynamic instability, increased intracranial pressure (use with caution)
Known hypersensitivity to halothane or other halogenated anesthetics; history of unexplained jaundice or fever after halothane administration; suspected or known hepatic injury from halogenated anesthetics; risk of malignant hyperthermia (including family history).
No specific food restrictions. However, propofol is formulated in a lipid emulsion containing soybean oil and egg lecithin, which may interact with high-fat meals theoretically but not clinically significant. Avoid alcohol for 24 hours post-procedure due to additive sedative effects.
No specific food interactions known, but fasting is required preoperatively to prevent aspiration pneumonitis caused by relaxation of the lower esophageal sphincter and loss of airway reflexes.
First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second trimester: No clear evidence of fetal harm. Third trimester: Use may cause neonatal respiratory depression, hypotonia, and neurobehavioral effects; risk of fetal bradycardia and hypoxia. Propofol crosses the placenta rapidly.
FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trimesters: Prolonged exposure may cause neonatal respiratory depression, hypotonia, and thermoregulatory instability; risk of fetal hypoxia due to maternal hypotension.
Propofol is excreted into breast milk in very low concentrations, with an estimated M/P ratio of 1.2-1.5. The relative infant dose is <0.1% of weight-adjusted maternal dose. Consider discarding milk for 24 hours after administration due to potential sedative effects on the infant.
Halothane is excreted in breast milk in low concentrations. M/P ratio not determined. Short-term use is considered compatible with breastfeeding; avoid prolonged or repeated exposure. Monitor infant for sedation and feeding difficulties.
Pregnancy increases volume of distribution and clearance of propofol by 20-50%, primarily due to increased cardiac output and hepatic blood flow. Induction doses may need to be increased by 15-30% to achieve desired effect. Maintenance infusion rates may also require upward titration.
Increased sensitivity to myocardial depression; reduce dose by 25-50% in pregnant patients. Monitor closely for hypotension. No specific pharmacokinetic adjustments required due to pregnancy, but consider decreased MAC (minimum alveolar concentration) in late pregnancy.
Propofol causes dose-dependent respiratory depression and apnea; always have airway equipment ready. It reduces cerebral metabolic rate and intracranial pressure, making it useful for neuroanesthesia. Pain on injection is common, particularly in small veins; consider lidocaine pretreatment. Propofol infusion syndrome (PRIS) is a rare but fatal complication with prolonged high-dose infusions (>48h, >4 mg/kg/h), characterized by lactic acidosis, rhabdomyolysis, and cardiac failure. Avoid in patients with egg or soy allergy due to lipid emulsion. Use the lower dose for elderly or hemodynamically unstable patients. Monitor triglyceride levels with prolonged use.
Halothane is a potent inhalational anesthetic with low blood-gas solubility, allowing rapid induction and emergence. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias, especially with epinephrine use. Halothane can cause hepatic necrosis, particularly with repeated exposure (halothane hepatitis). Avoid in patients with unexplained jaundice after prior halothane use. Use low concentrations with spontaneous ventilation to prevent respiratory depression.
This medication will cause you to feel very sleepy and lose consciousness quickly.,You may experience a burning or stinging sensation at the injection site; this is common.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,You might feel groggy, dizzy, or have a headache after waking up.,Inform your doctor if you have any allergies, especially to eggs, soy, or peanuts.,If you will be receiving this medication for a prolonged period, your doctor will monitor your heart, kidneys, and blood tests.
Avoid food or drink for at least 6-8 hours before surgery to reduce aspiration risk.,Report any history of liver disease or allergic reactions to anesthesia.,You may experience shivering or nausea after waking up from anesthesia.,Do not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you notice yellowing of skin or eyes, dark urine, or severe fatigue after surgery.
"Propofol, a general anesthetic, may inhibit CYP2C8, the primary enzyme responsible for rosiglitazone metabolism, leading to decreased clearance and elevated plasma concentrations of rosiglitazone. This interaction can potentiate the hypoglycemic effects of rosiglitazone, increasing the risk of hypoglycemia. Clinical vigilance is warranted when these agents are coadministered, especially in patients with diabetes."
"The combination of propofol and methyldopa can lead to an increased risk of severe hypotension and bradycardia due to additive cardiovascular depressant effects. Propofol causes peripheral vasodilation and direct myocardial depression, while methyldopa reduces sympathetic outflow and depletes catecholamines, enhancing propofol's hemodynamic effects. This interaction may result in profound hypotension, reduced cardiac output, and risk of organ hypoperfusion during anesthesia induction and maintenance."
"Propofol, a GABA-A receptor agonist and general anesthetic, depresses myocardial contractility and reduces systemic vascular resistance, leading to hypotension and bradycardia. Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, can blunt the compensatory tachycardia in response to propofol-induced vasodilation and myocardial depression. Concurrent use may result in additive negative chronotropic and inotropic effects, potentially causing severe bradycardia, hypotension, or reduced cardiac output, especially in patients with compromised cardiac function or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPOFOL vs FLUOTHANE, answered by our medical review team.
PROPOFOL is a General Anesthetic that works by Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.. FLUOTHANE is a General Anesthetic that works by Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPOFOL and FLUOTHANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPOFOL is: Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.. The standard adult dose of FLUOTHANE is: Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPOFOL and FLUOTHANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPOFOL is classified as Category A/B. First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second tr. FLUOTHANE is classified as Category C. FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.